ClinicalTrials.gg
CompletedNCT04797104LIBerate-FHUpdated Oct 27, 2026Results posted

Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction

A Phase 3 interventional study of lerodalcibep in Heterozygous Familial Hypercholesterolemia, sponsored by LIB Therapeutics LLC. Completed at 7 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by LIB Therapeutics LLC · Phase 3, Interventional, and Treatment

Updated Oct 27, 2026Results postedStudy documents posted+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
478
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Hyperlipoproteinemia Type II with a site in Israel — 5 open to participants now, 5 under way, 4 of them phase 3. Hyperlipoproteinemia Type II · Israel.

Enrollment
3rd of 11
478 · median 195
Started
2021
with 1 other
Phase 3
8 of 11
4 open now
Registered
5th of 11
by date
Lead sponsor
3 of 11
LIB Therapeutics LLC

Among the 11 studies in Hyperlipoproteinemia Type II with a site in Israel, this one is the 3rd largest by enrollment, is one of 2 that started in 2021, is one of 8 in phase 3, and was the 5th registered.

Hyperlipoproteinemia Type II

249 studies on the registry are indexed under Hyperlipoproteinemia Type II; 56 are open to participants now.

Browse Hyperlipoproteinemia Type II studies →

Open to participants now

5 of the 11 studies in Hyperlipoproteinemia Type II with a site in Israel are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 36 Hyperlipoproteinemia Type II studies recruiting now, 17 (47%) set no upper age limit and 15 (42%) stop at 75 or younger; 17 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Hyperlipoproteinemia Type II with a site in Israel, or all of them as a file.
02

Study summary

This study is to assess LDL-C reductions at Week 24 and the mean of Weeks 22 and 24 with monthly Q4W (≤31 days) dosing of LIB003 300 mg administered subcutaneously (SC) compared to placebo in patients 18 years or older with Heterozygous FH on stable diet and oral LDL-C lowering drug therapy.

Read the detailed description

A randomized, double-blind, placebo-controlled, Phase 3 study of 24 weeks duration. Approximately 600 males and females aged ≥18 years with clinical or genetic heterozygous FH who fulfill the inclusion and exclusion criteria will be enrolled. Patients will be randomized in a 2:1 ratio to LIB003 (400 patients) or placebo (200 patients) administered SC Q4W (≤31 days). The study will consist of a Screening Period and a Treatment Period. The total study duration will be up to 35 weeks which includes up to an 11-week Screening Period (which may include up to a 8-week washout) and 24 weeks of study drug treatment.

03

Conditions studied

  • Heterozygous Familial Hypercholesterolemia

Keywords

  • lerodalcibep
  • PCSK9 inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of written and signed prior to any study-specific procedure;
  • Weight of ≥40 kg (88 lbs) and (BMI) ≥17 and ≤42 kg/m2;
  • Diagnosis of definite, probable or possible HeFH based either on clinical criteria (Simon Broome register criteria or Dutch Lipid Clinics [DLC] Network Criteria) or genotyping and at the defined eligibility visit (screening or post washout/stabilization)
  • LDL-C ≥70 mg/dL (if very-high risk for CVD) or ≥100 mg/dL (if high risk for CVD) and TG ≤400 mg/dL while on stable lipid lowering oral drug therapy (eg, maximally tolerated statin with or without ezetimibe); Patients unable to tolerate approved doses of a statin may take lower than approved doses and less frequently than daily as long as the dose and dosing frequency is consistent.
  • Patients with documentation of inability to tolerate any statin at any dose, or history of rhabdomyolysis, and unable to tolerate any other allowed oral lipid lowering agent, and thus on no lipid lowering therapy must have an LDL-C ≥190 mg/dL (4.9 mmol/L) at the Screening Visit unless they have a documented pathogenic FH variant;
  • Stable diet and other lipid lowering oral therapies besides statins and ezetimibe including bile-acid sequestrants, OM-3 compounds, fenofibrate, bezafibrate, nicotinic acid and bempedoic acid or combinations thereof for at least 4 weeks
  • Patients on a PCSK9 mAb at a dose of 75 mg, 140 mg, or 150 mg Q2W must undergo a of ≥4 weeks after the last dose; for those on a dose of 300 mg or 420 mg Q4W (≤31 days) the washout period is ≥8 weeks following last dose;
  • Females of must be using a highly effective form of if sexually active and have negative urine pregnancy test at the last Screening Visit

Exclusion criteria

Exclusion Criteria:

  • Use of prohibited oral lipid lowering agents mipomersen or lomitapide within 6 months of screening, gemfibrozil within 6 weeks of the Screening Visit or LDL/plasma apheresis within 2 months prior to Day 1;
  • Documented history of HoFH defined clinically or genetically
  • History of any prior or active clinical condition or acute and/or unstable systemic disease compromising patient inclusion, at the discretion of the Investigator.
  • Females of who are sexually active, not using or unwilling to use a highly effective form of , pregnant or breastfeeding, or who have a positive urine pregnancy test at the last Screening Visit;
  • Moderate to severe renal dysfunction, defined as an \<30 mL/min/1.73m2
  • Active liver disease or hepatic dysfunction, history of liver transplant, and/or or ALT >2.5 × the
  • Uncontrolled thyroid disease: hyperthyroidism or hypothyroidism as defined by TSH \<LLN or >1.5 × ULN, respectively,
  • Uncontrolled Type 1 or Type 2 DM (fasting glucose≥200 mg/dL or of ≥9%;
  • Planned cardiac surgery or revascularization;
  • III-IV heart failure
  • Previous treatment with LIB003 or any adnectin product;
  • Any other finding which, in the opinion of the Investigator, would compromise the patient's safety or participation in the study
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
478 participants (actual)

Study arms

  • Experimental
    LIB003 (lerodalcibep)

    300 mg (1.2 mL) SC Q4W

    Drug: lerodalcibep

  • Placebo comparator
    Placebo

    1.2 mL SC Q4W

    Drug: lerodalcibep

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline Compared to Placebo in LDL-C Level Calculated by Friedwald Formula at Week 24

    Blood samples were collected at baseline and Week 24 to determine mean percent change in LDL-C (calculated by the Friedwald formula). Percent change from baseline determined using analysis of covariance (ANCOVA) model with treatment and CVD status as factors and baseline LDL-C value as covariate.

    Time frame: Baseline and Week 24

  2. Change From Baseline Compared to Placebo in LDL-C Level Calculated by Friedwald Formula Using the Mean of Weeks 22 and 24

    Blood samples were collected at baseline Week 22 and Week 24 to determine mean percent change in LDL-C (calculated by the Friedwald formula). Percent change from baseline determined using analysis of covariance (ANCOVA) model with treatment and CVD status as factors and baseline LDL-C value as covariate.

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Change From Baseline Compared to Placebo in LDL-C Level Calculated by Hopkins Level at Week 24

    Blood samples were collected at baseline and Week 24 to determine mean percent change in LDL-C (calculated by the Hopkins formula). Percent change from baseline determined using analysis of covariance (ANCOVA) model with treatment and CVD status as factors and baseline LDL-C value as covariate.

    Time frame: Baseline and Week 24

  2. Change From Baseline Compared to Placebo in LDL-C Level Calculated by Hopkins Formula Using the Mean of Weeks 22 and 24

    Blood samples were collected at baseline Week 22 and Week 24 to determine mean percent change in LDL-C (calculated by the Friedwald formula). Percent change from baseline determined using analysis of covariance (ANCOVA) model with treatment and CVD status as factors and baseline LDL-C value as covariate.

    Time frame: Baseline and Weeks 22 and 24

  3. Change From Baseline Compared to Placebo in LDL-C Level Measured by Preparative Ultracentrifugation at Week 24

    Blood samples were collected at baseline and Week 24 to determine mean percent change in LDL-C (measured by preparative ultracentrifugation). Percent change from baseline determined using analysis of covariance (ANCOVA) model with treatment and CVD status as factors and baseline LDL-C value as covariate.

    Time frame: Baseline and Week 24

  4. Change From Baseline Compared to Placebo on Serum Unbound (Free) Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Concentrations at Week 24

    Blood samples were collected at baseline and Week 24 to determine mean percent change in free PCSK9 concentrations. Percent change from baseline determined using analysis of covariance (ANCOVA) model with treatment and CVD status as factors and baseline LDL-C value as covariate.

    Time frame: Baseline and Week 24

  5. Change From Baseline Compared to Placebo in Apolipoprotein B (Apo B) at Week 24

    Blood samples were collected at baseline and Week 24 to determine mean percent change in apo B. Percent change from baseline determined using analysis of covariance (ANCOVA) model with treatment and CVD status as factors and baseline apo B value as covariate.

    Time frame: Baseline to Week 24

  6. Change From Baseline Compared to Placebo in Lipoprotein(a) at Week 24

    Blood samples were collected at baseline and Week 24 to determine mean percent change in Lp(a). Percent change from baseline determined using analysis of covariance (ANCOVA) model with treatment and CVD status as factors and baseline Lp(a) value as covariate.

    Time frame: Baseline and Week 24

07

Results

Posted Sep 28, 2026

Participant flow

Participant flow — Overall Study
MilestoneLIB003 (Lerodalcibep)Placebo
Started319159
Completed306155
Not completed134
Withdrew: Adverse event54
Withdrew: Withdrawal by subject70
Withdrew: Physician decision10

Outcome measures

PrimaryChange From Baseline Compared to Placebo in LDL-C Level Calculated by Friedwald Formula at Week 24

Blood samples were collected at baseline and Week 24 to determine mean percent change in LDL-C (calculated by the Friedwald formula). Percent change from baseline determined using analysis of covariance (ANCOVA) model with treatment and CVD status as factors and baseline LDL-C value as covariate.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Percent Change
Change From Baseline Compared to Placebo in LDL-C Level Calculated by Friedwald Formula at Week 24
Percent ChangeLIB003 (Lerodalcibep)Placebo
Change From Baseline Compared to Placebo in LDL-C Level Calculated by Friedwald Formula at Week 24-52.32 ± 1.8668.21 ± 2.609
Statistical analysis
  • LIB003 (Lerodalcibep) vs Placebo · ANCOVA · p = <.0001 · Least squares mean difference: -60.53 · 95% CI -66.72 to -54.34
SecondaryChange From Baseline Compared to Placebo in LDL-C Level Calculated by Hopkins Level at Week 24

Blood samples were collected at baseline and Week 24 to determine mean percent change in LDL-C (calculated by the Hopkins formula). Percent change from baseline determined using analysis of covariance (ANCOVA) model with treatment and CVD status as factors and baseline LDL-C value as covariate.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Percent Change
Change From Baseline Compared to Placebo in LDL-C Level Calculated by Hopkins Level at Week 24
Percent ChangeLIB003 (Lerodalcibep)Placebo
Change From Baseline Compared to Placebo in LDL-C Level Calculated by Hopkins Level at Week 24-50.85 ± 1.8468.35 ± 2.582
Statistical analysis
  • LIB003 (Lerodalcibep) vs Placebo · ANCOVA · p = <.0001 · Least squares mean difference: -59.20 · 95% CI -65.33 to -53.07
PrimaryChange From Baseline Compared to Placebo in LDL-C Level Calculated by Friedwald Formula Using the Mean of Weeks 22 and 24

Blood samples were collected at baseline Week 22 and Week 24 to determine mean percent change in LDL-C (calculated by the Friedwald formula). Percent change from baseline determined using analysis of covariance (ANCOVA) model with treatment and CVD status as factors and baseline LDL-C value as covariate.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Percent Change
Change From Baseline Compared to Placebo in LDL-C Level Calculated by Friedwald Formula Using the Mean of Weeks 22 and 24
Percent ChangeLIB003 (Lerodalcibep)Placebo
Change From Baseline Compared to Placebo in LDL-C Level Calculated by Friedwald Formula Using the Mean of Weeks 22 and 24-60.96 ± 1.6257.31 ± 2.272
Statistical analysis
  • LIB003 (Lerodalcibep) vs Placebo · ANCOVA · p = <.0001 · Least squares mean difference: -68.27 · 95% CI -73.66 to -62.88
SecondaryChange From Baseline Compared to Placebo in LDL-C Level Calculated by Hopkins Formula Using the Mean of Weeks 22 and 24

Blood samples were collected at baseline Week 22 and Week 24 to determine mean percent change in LDL-C (calculated by the Friedwald formula). Percent change from baseline determined using analysis of covariance (ANCOVA) model with treatment and CVD status as factors and baseline LDL-C value as covariate.

Time frame:
Baseline and Weeks 22 and 24
Reported as:
Least squares mean · Percent Change
Change From Baseline Compared to Placebo in LDL-C Level Calculated by Hopkins Formula Using the Mean of Weeks 22 and 24
Percent ChangeLIB003 (Lerodalcibep)Placebo
Change From Baseline Compared to Placebo in LDL-C Level Calculated by Hopkins Formula Using the Mean of Weeks 22 and 24-59.38 ± 1.6157.51 ± 2.259
Statistical analysis
  • LIB003 (Lerodalcibep) vs Placebo · ANCOVA · p = <.0001 · Least squares mean difference: -66.89 · 95% CI -72.25 to -61.53
SecondaryChange From Baseline Compared to Placebo in LDL-C Level Measured by Preparative Ultracentrifugation at Week 24

Blood samples were collected at baseline and Week 24 to determine mean percent change in LDL-C (measured by preparative ultracentrifugation). Percent change from baseline determined using analysis of covariance (ANCOVA) model with treatment and CVD status as factors and baseline LDL-C value as covariate.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Percent Change
Change From Baseline Compared to Placebo in LDL-C Level Measured by Preparative Ultracentrifugation at Week 24
Percent ChangeLIB003 (Lerodalcibep)Placebo
Change From Baseline Compared to Placebo in LDL-C Level Measured by Preparative Ultracentrifugation at Week 24-49.65 ± 1.7818.23 ± 2.491
Statistical analysis
  • LIB003 (Lerodalcibep) vs Placebo · ANCOVA · p = <.0001 · Least squares mean difference: -57.88 · 95% CI -63.79 to -51.97
SecondaryChange From Baseline Compared to Placebo on Serum Unbound (Free) Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Concentrations at Week 24

Blood samples were collected at baseline and Week 24 to determine mean percent change in free PCSK9 concentrations. Percent change from baseline determined using analysis of covariance (ANCOVA) model with treatment and CVD status as factors and baseline LDL-C value as covariate.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Percent Change
Change From Baseline Compared to Placebo on Serum Unbound (Free) Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Concentrations at Week 24
Percent ChangeLIB003 (Lerodalcibep)Placebo
Change From Baseline Compared to Placebo on Serum Unbound (Free) Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Concentrations at Week 24-68.97 ± 2.299-3.97 ± 8.511
Statistical analysis
  • LIB003 (Lerodalcibep) vs Placebo · ANCOVA · p = <.0001 · Least squares mean difference: -65.01 · 95% CI -82.24 to -47.77
SecondaryChange From Baseline Compared to Placebo in Apolipoprotein B (Apo B) at Week 24

Blood samples were collected at baseline and Week 24 to determine mean percent change in apo B. Percent change from baseline determined using analysis of covariance (ANCOVA) model with treatment and CVD status as factors and baseline apo B value as covariate.

Time frame:
Baseline to Week 24
Reported as:
Least squares mean · Percent Change
Change From Baseline Compared to Placebo in Apolipoprotein B (Apo B) at Week 24
Percent ChangeLIB003 (Lerodalcibep)Placebo
Change From Baseline Compared to Placebo in Apolipoprotein B (Apo B) at Week 24-47.6 ± 1.574.6 ± 2.19
Statistical analysis
  • LIB003 (Lerodalcibep) vs Placebo · ANCOVA · p = <.0001 · Least squares mean difference: -52.2 · 95% CI -57.4 to -47.0
SecondaryChange From Baseline Compared to Placebo in Lipoprotein(a) at Week 24

Blood samples were collected at baseline and Week 24 to determine mean percent change in Lp(a). Percent change from baseline determined using analysis of covariance (ANCOVA) model with treatment and CVD status as factors and baseline Lp(a) value as covariate.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Percent Change
Change From Baseline Compared to Placebo in Lipoprotein(a) at Week 24
Percent ChangeLIB003 (Lerodalcibep)Placebo
Change From Baseline Compared to Placebo in Lipoprotein(a) at Week 24-19.40 ± 3.0463.73 ± 4.267
Statistical analysis
  • LIB003 (Lerodalcibep) vs Placebo · ANCOVA · p = <.0001 · Least squares mean difference: -23.13 · 95% CI -33.24 to -13.02

Adverse events

Collected over From Baseline through week 24. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LIB003 (Lerodalcibep)0/318 (0%)10/318 (3.1%)230/318 (72.3%)
Placebo1/159 (0.6%)9/159 (5.7%)109/159 (68.6%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventLIB003 (Lerodalcibep)Placebo
Angina pectorisCardiac disorders2/3180/159
Acute myocardial infarctionCardiac disorders0/3181/159
Myocardial infarctionCardiac disorders0/3181/159
Myocardial ischaemiaCardiac disorders0/3181/159
ArthralgiaMusculoskeletal and connective tissue disorders0/3181/159
Rotator cuff syndromeMusculoskeletal and connective tissue disorders0/3181/159
Alanine aminotransferase increasedInvestigations0/3181/159
Adenocarcinoma of colonNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3181/159
Ischaemic strokeNervous system disorders0/3181/159
Pneumothorax spontaneousRespiratory, thoracic and mediastinal disorders0/3181/159
Most frequent other events
Showing 10 of 25
Most frequent other events
EventLIB003 (Lerodalcibep)Placebo
COVID-19Infections and infestations35/31817/159
Injection site reactionGeneral disorders32/3182/159
ArthralgiaMusculoskeletal and connective tissue disorders13/31813/159
Injection site erythemaGeneral disorders23/3181/159
Upper respiratory tract infectionInfections and infestations18/31811/159
NasopharyngitisInfections and infestations16/3183/159
Urinary tract infectionInfections and infestations10/3188/159
HypertensionVascular disorders15/3186/159
GastroenteritisInfections and infestations14/3184/159
HeadacheNervous system disorders12/3185/159

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)LIB003 (Lerodalcibep)PlaceboTotal
<=18 years000
Between 18 and 65 years259130389
>=65 years602989
Sex: Female, Male
Sex: Female, Male(Participants)LIB003 (Lerodalcibep)PlaceboTotal
Female16483247
Male15576231
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)LIB003 (Lerodalcibep)PlaceboTotal
Hispanic or Latino224
Not Hispanic or Latino315157472
Unknown or Not Reported202
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)LIB003 (Lerodalcibep)PlaceboTotal
White273143416
Black or African American251237
Asian21425
Region of Enrollment
Region of Enrollment(Participants)LIB003 (Lerodalcibep)PlaceboTotal
South Africa17481255
Turkey372966
New Zealand382260
Norway26733
Spain101222
India14317
Israel10212
Canada628
United States415
Baseline Low-density Lipoprotein Cholesterol (LDL-C) by Friedewald Formula (mg/dL)
Baseline Low-density Lipoprotein Cholesterol (LDL-C) by Friedewald Formula (mg/dL)(mg/dL)LIB003 (Lerodalcibep)PlaceboTotal
Mean152.1 ± 67.42146.4 ± 56.87150.2 ± 64.10
Baseline Low-density Lipoprotein Cholesterol (LDL-C) by Hopkins Formula (mg/dL)
Baseline Low-density Lipoprotein Cholesterol (LDL-C) by Hopkins Formula (mg/dL)(mg/dL)LIB003 (Lerodalcibep)PlaceboTotal
Mean153.5 ± 67.28147.2 ± 56.77151.4 ± 63.98
Baseline Low-density Lipoprotein Cholesterol (LDL-C) by Preparative Ultracentrifugation (mg/dL)
Baseline Low-density Lipoprotein Cholesterol (LDL-C) by Preparative Ultracentrifugation (mg/dL)(mg/dL)LIB003 (Lerodalcibep)PlaceboTotal
Mean149.3 ± 64.10144.7 ± 53.66147.8 ± 60.81

1 further baseline measures are reported on the registry.

08

Study locations

7 sites
  • Metabolic & Atherosclerosis Research Center (MARC)
    Cincinnati, Ohio 45227, United States
  • Department of Medicine, Hadassah University Hospital
    Jerusalem, Jerusalem 12000, Israel
  • Rabin Medical Center, Beilinson Hospital,
    Petah Tikva, 49100, Israel
  • Lipid Clinic, Oslo University Hospital
    Oslo, 0586, Norway
  • Carbohydrate and Lipid Metabolism Research Unit
    Johannesburg, Gauteng 2193, South Africa
  • Division of Lipidology, Department of Medicine University of Cape Town
    Cape Town, Western Province 7925, South Africa
  • Ege University Medical School
    Izmir, Bornova 35040, Turkey (Türkiye)
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Jul 2023, 27 months.

Results were first posted in Sep 2026, 3 years 1 month after primary completion.

Of 29 industry-sponsored phase 3 interventional studies under Hyperlipoproteinemia Type II, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 34. This study's 27 months is above that.

Counting every sponsor, half of 33 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2021
First posted
Mar 15, 2021
StartActual
Apr 22, 2021
Primary completionActual
Jul 30, 2023
CompletionActual
Dec 5, 2023
Results first posted
Sep 28, 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted, then revised
posted Sep 28, 2026 · revised Oct 27, 2026
Sites
2 sites added, 2 sites removed — first site in Turkey (Türkiye); no longer in Turkey
Show 2 added (1 Turkey (Türkiye), 1 Israel)
  • Ege University Medical School · Izmir, Turkey (Türkiye)
  • Department of Medicine, Hadassah University Hospital · Jerusalem, Israel
Show 2 removed
  • Ege University Medical School · İzmir, Turkey
  • Department of Medicine, Hadassah University Hospital · Jerusalem, Israel
across 2 updates, Sep 28, 2026 – Oct 27, 2026
Primary outcomes
1 edited, 1 added
What changed in the outcomes
  • EditedChange from baseline comparedFrom Baseline Compared to placeboPlacebo in LDL-C levelLevel Calculated by Friedwald Formula at Week 24Time frame: 24 weeks → Baseline and Week 24
  • AddedChange From Baseline Compared to Placebo in LDL-C Level Calculated by Friedwald Formula Using the Mean of Weeks 22 and 24Time frame: Baseline and Week 24
Sep 28, 2026
Documents
Secondary outcomes
Revised in 2 updates
What changed on Sep 28, 2026
  • AddedChange From Baseline Compared to Placebo in LDL-C Level Calculated by Hopkins Level at Week 24Time frame: Baseline and Week 24
  • AddedChange From Baseline Compared to Placebo in LDL-C Level Calculated by Hopkins Formula Using the Mean of Weeks 22 and 24Time frame: Baseline and Weeks 22 and 24
  • AddedChange From Baseline Compared to Placebo in LDL-C Level Measured by Preparative Ultracentrifugation at Week 24Time frame: Baseline and Week 24
  • AddedChange From Baseline Compared to Placebo on Serum Unbound (Free) Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Concentrations at Week 24Time frame: Baseline and Week 24
  • AddedChange From Baseline Compared to Placebo in Apolipoprotein B (Apo B) at Week 24Time frame: Baseline to Week 24
  • AddedChange From Baseline Compared to Placebo in Lipoprotein(a) at Week 24Time frame: Baseline and Week 24
  • RemovedIncidence of Treatment-Emergent Adverse Events as assessed by Medical Dictionary for Regulatory ActivitiesTime frame: 24 weeks
  • RemovedChange in serum free PCSK9 with LIB003 compared to placeboTime frame: 24 weeks
What changed on Oct 27, 2026
  • DescriptionChange From Baseline Compared to Placebo in Lipoprotein(a) at Week 24: how it is measured was reworded
across 2 updates, Sep 28, 2026 – Oct 27, 2026
Show all 2 updates
  1. Oct 27, 2026
    Posted results revised
    1 site added, 1 site removed
    Show site
    • Department of Medicine, Hadassah University Hospital · Jerusalem, Israel
    Show 1 removed
    • Department of Medicine, Hadassah University Hospital · Jerusalem, Israel
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionChange From Baseline Compared to Placebo in Lipoprotein(a) at Week 24: how it is measured was reworded
  2. Sep 28, 2026
    Results posted
    1 site added, 1 site removed — first site in Turkey (Türkiye); no longer in Turkey
    Show site
    • Ege University Medical School · Izmir, Turkey (Türkiye)
    Show 1 removed
    • Ege University Medical School · İzmir, Turkey
    Primary outcomes 1 edited, 1 added
    What changed in the outcomes
    • EditedChange from baseline comparedFrom Baseline Compared to placeboPlacebo in LDL-C levelLevel Calculated by Friedwald Formula at Week 24Time frame: 24 weeks → Baseline and Week 24
    • AddedChange From Baseline Compared to Placebo in LDL-C Level Calculated by Friedwald Formula Using the Mean of Weeks 22 and 24Time frame: Baseline and Week 24
    Secondary outcomes 6 added, 2 removed
    What changed in the outcomes
    • AddedChange From Baseline Compared to Placebo in LDL-C Level Calculated by Hopkins Level at Week 24Time frame: Baseline and Week 24
    • AddedChange From Baseline Compared to Placebo in LDL-C Level Calculated by Hopkins Formula Using the Mean of Weeks 22 and 24Time frame: Baseline and Weeks 22 and 24
    • AddedChange From Baseline Compared to Placebo in LDL-C Level Measured by Preparative Ultracentrifugation at Week 24Time frame: Baseline and Week 24
    • AddedChange From Baseline Compared to Placebo on Serum Unbound (Free) Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Concentrations at Week 24Time frame: Baseline and Week 24
    • AddedChange From Baseline Compared to Placebo in Apolipoprotein B (Apo B) at Week 24Time frame: Baseline to Week 24
    • AddedChange From Baseline Compared to Placebo in Lipoprotein(a) at Week 24Time frame: Baseline and Week 24
    • RemovedIncidence of Treatment-Emergent Adverse Events as assessed by Medical Dictionary for Regulatory ActivitiesTime frame: 24 weeks
    • RemovedChange in serum free PCSK9 with LIB003 compared to placeboTime frame: 24 weeks
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04797104
Lead sponsor
LIB Therapeutics LLC
Collaborators
Medpace, Inc.
Responsible party
Sponsor
First posted
Mar 15, 2021
Start date
Apr 22, 2021
Primary completion
Jul 30, 2023
Completion
Dec 5, 2023
Results posted
Sep 28, 2026
Last update
Oct 27, 2026

Study contacts

David Kallend, MB BCh
study director · LIB Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lerodalcibep

Start the discussion